Peregrine Pharmaceuticals reported $61K in Ordinary Share Capital for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ordinary Share Capital Change
Acceleron Pharma XLRN:US $ 0.06M 0M
Adamas Pharmaceuticals ADMS:US 50K 0
Amgen AMGN:US $ 31989M 112M
AstraZeneca AZN:LN 387M 59M
Bristol Myers Squibb BMY:US $ 292M 0M
Celldex Therapeutics CLDX:US $ 0.05M 0.01M
Chemocentryx CCXI:US $ 0.07M 0M
Dicerna Pharmaceuticals DRNA:US $ 0.01M 0M
Eli Lilly And LLY:US $ 598.2M 0.1M
Flexion Therapeutics FLXN:US $ 50K 0
GlaxoSmithKline GSK:LN 1347M 0M
Intrexon XON:US $ 0M 0M
Karyopharm Therapeutics KPTI:US $ 8K 0
Kindred Biosciences KIN:US $ 0M 0M
Macrogenics MGNX:US $ 0.61M 0.01M
Mannkind MNKD:US $ 2.5M 0.01M
Minerva Neurosciences NERV:US $ 0M 0M
Newlink Genetics NLNK:US $ 0.08M 0M
Novartis NOVN:VX SF 901M 12M
Novavax NVAX:US $ 0.76M 0.01M
Repligen RGEN:US $ 0.55M 0M
Xencor XNCR:US $ 0.58M 0M